“Our new website is not only bold and attractive, it was built with the end user in mind, said Joe Conda, President of Triplefin and H. D Smith Specialty Solutions (a division of H. D Smith).
(PRWEB) February 17, 2015
Triplefin, a subsidiary of H. D. Smith, announced today its newly designed website, Triplefin.com. The new site provides the ultimate user-friendly experience with improved navigation and functionality.
The new website integrates a robust section for Triplefin’s innovative patient access and adherence solutions with quick, intuitive entry to information about technology and helpful resources, such as case studies and white papers. Visitors can monitor Triplefin’s company news and attendance at pharmaceutical industry conferences and special meetings, and they can explore the careers page for employment information. With rich content that is easy to navigate, Triplefin.com is also accessible across multiple devices – desktop, tablet and smartphone.
“Our new website is not only bold and attractive, it was built with the end user in mind, said Joe Conda, President of Triplefin and H. D Smith Specialty Solutions (a division of H. D Smith). “Pharmaceutical manufacturers can easily locate useful information about our products and services. It offers a remarkable first impression of Triplefin and serves as the gateway to our company.”
Triplefin, headquartered in Cincinnati, Ohio, is operating as a wholly owned subsidiary of H. D. Smith. A leading pharmaceutical brand support company for 33 years, Triplefin removes barriers to patient access and adherence with innovative products and services. Together with H. D. Smith, Triplefin provides an end-to-end solution that includes the Rx365™ suite of digital solutions (benefits verification, prior authorization and card activation), patient assistance, patient reimbursement and patient adherence programs, co-pay and voucher solutions, sample fulfillment and sampling solutions, pharmacy services, third party logistics and the National Specialty Pharmacy Nursing Network (SPNN).
Today, more than 50 pharmaceutical manufacturing companies (including 11 of the top 15), representing more than 150 brands across multiple therapeutic categories, have partnered with Triplefin to create strategic programs for patient access.